《大行報告》匯豐研究下調基建股目標價 偏好中鐵(00390.HK)及中國建築國際(03311.HK)
匯豐發表研究報告指,中國政府的持續財政支援,或促使基建投資增長在2022財年達高單位數,該行預期第三季的基建訂單加快,令主要基建商的現金流改善。該行看好中鐵(00390.HK)及中國建築國際(03311.HK),均予「買入」評級,惟將中鐵目標價由6.1元下調至5.9元,而中國建築國際則維持12.5元。
該行指出,大部分營造商在上半年錄得現金流改善,料該趨勢將在下半年持續,預計2022財年主要合約營造商的盈利將按年增長14至20%。該行又表示,過去數個月行業表現疲弱,主要是由於資本轉動及相關的地產發展商風險,但認為大型基建企業會受惠於行業整合及宏觀因素支持基建發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.